Tvardi Q3 Loss Widens to $6.1M; Cash Runway to Q3 2027, HCC Data Early Q1 2027
TVRD sits 44% above its 52-week low of $0.773.
Summary
Tvardi reported a $6.1 million Q3 net loss and held $22.3 million in cash, enough to fund operations into Q3 2027. Topline data for TTI-101 in liver cancer is now expected early Q1 2027, while the TTI-109 ulcerative colitis program still requires IND clearance and new funding.
Key Events · Earnings and Guidance · TVRD
-
Q3 Net Loss Widens to $6.1M
Net loss was $6.1 million, or $(0.48) per share, versus $5.5 million, or $(0.59) per share, a year earlier. R&D rose to $4.5 million from $3.6 million on higher TTI-101 clinical costs.
-
Cash Runway Into Q3 2027
Cash and cash equivalents were $22.3 million at September 30, 2026, down from $30.8 million in cash, cash equivalents and short-term investments at December 31, 2025. Management expects this to fund operations into the third quarter of 2027.
-
TTI-109 UC Launch Needs Funding
Tvardi is preparing to advance TTI-109 into ulcerative colitis in 2027, but only subject to IND clearance and additional funding — meaning a capital raise is required before that trial starts.
-
HCC Topline Data Early Q1 2027
Topline data from the Phase 1b/2 REVERT LIVER CANCER study of TTI-101 in hepatocellular carcinoma is now expected early in the first quarter of 2027, allowing for complete cohort evaluation.
Analysis · TVRD · Life Sciences
For a clinical-stage company, the runway is the whole story: Tvardi burned $6.1 million in the third quarter and ended September with $22.3 million in cash, which management says funds operations into the third quarter of 2027. That buys roughly three more quarters, but the TTI-109 ulcerative colitis program cannot start without new money and IND clearance, so a raise is effectively required before the 2027 launch. The near-term stock mover is the TTI-101 liver cancer topline, now guided to early Q1 2027 after being pushed out to allow complete cohort evaluation. Share count already climbed to 13.3 million from 9.4 million at year-end 2025, reflecting prior ATM sales, so any future financing lands on an already-diluted base.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVRD was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $0.77 to $5.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.